BSE Live
Nov 12, 16:01Prev. Close
1211.35
Open Price
1221.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 12, 15:59Prev. Close
1211.50
Open Price
1220.10
Bid Price (Qty.)
1229.60 (211)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | |
| Total Share Capital | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | |
| Reserves and Surplus | 33,466.20 | 28,171.40 | 23,202.80 | 19,129.20 | 17,558.50 | |
| Total Reserves and Surplus | 33,466.20 | 28,171.40 | 23,202.80 | 19,129.20 | 17,558.50 | |
| Total Shareholders Funds | 33,549.60 | 28,254.80 | 23,286.10 | 19,212.40 | 17,641.70 | |
| Minority Interest | 377.80 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 380.00 | 380.00 | 0.00 | 380.00 | 380.00 | |
| Deferred Tax Liabilities [Net] | 1,403.80 | 84.10 | 76.00 | 1.40 | 28.90 | |
| Other Long Term Liabilities | 651.80 | 533.00 | 331.00 | 361.50 | 411.60 | |
| Long Term Provisions | 29.80 | 23.90 | 19.90 | 25.80 | 50.80 | |
| Total Non-Current Liabilities | 2,465.40 | 1,021.00 | 426.90 | 768.70 | 871.30 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 3,804.50 | 1,272.30 | 1,119.00 | 2,708.20 | 2,314.50 | |
| Trade Payables | 2,647.80 | 2,614.40 | 2,268.40 | 2,266.20 | 1,810.90 | |
| Other Current Liabilities | 5,805.90 | 5,009.30 | 4,532.20 | 4,204.80 | 3,476.90 | |
| Short Term Provisions | 775.60 | 692.00 | 652.50 | 586.60 | 501.50 | |
| Total Current Liabilities | 13,033.80 | 9,588.00 | 8,572.10 | 9,765.80 | 8,103.80 | |
| Total Capital And Liabilities | 49,426.60 | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 7,298.40 | 6,248.70 | 5,654.20 | 4,886.90 | 4,732.20 | |
| Intangible Assets | 9,614.10 | 3,626.80 | 3,017.50 | 2,687.30 | 2,913.60 | |
| Capital Work-In-Progress | 2,399.40 | 1,351.00 | 975.20 | 1,279.60 | 953.90 | |
| Fixed Assets | 19,378.10 | 11,294.80 | 9,701.80 | 8,867.60 | 9,210.90 | |
| Non-Current Investments | 720.40 | 525.50 | 536.20 | 598.60 | 833.30 | |
| Deferred Tax Assets [Net] | 1,832.50 | 1,057.80 | 705.20 | 1,277.00 | 1,068.60 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 1,163.60 | 630.30 | 369.00 | 674.10 | 393.80 | |
| Total Non-Current Assets | 24,408.50 | 14,058.50 | 11,859.60 | 11,964.60 | 12,066.50 | |
| CURRENT ASSETS | ||||||
| Current Investments | 3,330.70 | 4,405.00 | 4,449.60 | 2,017.30 | 1,378.50 | |
| Inventories | 7,108.50 | 6,355.20 | 4,867.00 | 5,088.40 | 4,541.20 | |
| Trade Receivables | 9,042.00 | 8,029.80 | 7,248.50 | 6,676.40 | 4,964.10 | |
| Cash And Cash Equivalents | 2,460.20 | 1,727.70 | 1,730.20 | 2,419.20 | 2,078.80 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 3,076.70 | 4,287.60 | 2,130.20 | 1,581.00 | 1,587.70 | |
| Total Current Assets | 25,018.10 | 24,805.30 | 20,425.50 | 17,782.30 | 14,550.30 | |
| Total Assets | 49,426.60 | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,738.10 | 2,091.80 | 997.40 | 936.80 | 1,077.40 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 55.87 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
11.11.2025
30.10.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz